相似文献
1
Response to the letter Re: Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting.
ESMO Open. 2025 Jun 17;10(7):105297. doi: 10.1016/j.esmoop.2025.105297.
2
Letter re: Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting: Are real-world data sufficient to draw a comparison between CDK4/6 inhibitors?
ESMO Open. 2025 Jun;10(6):105296. doi: 10.1016/j.esmoop.2025.105296. Epub 2025 May 29.
3
Cost-effectiveness of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer: a systematic review and meta-analysis.
Curr Med Res Opin. 2024 Oct;40(10):1753-1767. doi: 10.1080/03007995.2024.2402074. Epub 2024 Sep 21.
4
QT STAR: concomitant QTc-prolonging medication use among patients with HR+/HER2- metastatic breast cancer receiving a CDK4/6 inhibitor in first line.
Cardiooncology. 2025 Jul 4;11(1):64. doi: 10.1186/s40959-025-00364-z.
5
A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer.
EBioMedicine. 2025 Jun 26;118:105828. doi: 10.1016/j.ebiom.2025.105828.
6
Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study.
Thorac Cancer. 2024 Apr;15(12):965-973. doi: 10.1111/1759-7714.15282. Epub 2024 Mar 13.
7
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
Cochrane Database Syst Rev. 2007 Jan 24(1):CD003370. doi: 10.1002/14651858.CD003370.pub2.
8
Real-world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first- or second-line treatment for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.
Breast Cancer. 2025 May 20. doi: 10.1007/s12282-025-01713-7.
9
Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis.
Arch Gynecol Obstet. 2025 Feb;311(2):423-427. doi: 10.1007/s00404-024-07761-2. Epub 2024 Oct 7.
10
Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.
Future Oncol. 2024 Apr;20(12):761-780. doi: 10.2217/fon-2023-0858. Epub 2024 Jan 17.
本文引用的文献
1
Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting.
ESMO Open. 2025 Jan;10(1):104103. doi: 10.1016/j.esmoop.2024.104103. Epub 2025 Jan 3.
2
NCCN Guidelines® Insights: Breast Cancer, Version 4.2023.
J Natl Compr Canc Netw. 2023 Jun;21(6):594-608. doi: 10.6004/jnccn.2023.0031.
3
The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This?
Cancer Manag Res. 2021 Nov 10;13:8457-8471. doi: 10.2147/CMAR.S328058. eCollection 2021.
4
Real-world data: towards achieving the achievable in cancer care.
Nat Rev Clin Oncol. 2019 May;16(5):312-325. doi: 10.1038/s41571-019-0167-7.
5
Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?
Biomed Res Int. 2015;2015:865101. doi: 10.1155/2015/865101. Epub 2015 Jun 16.
Zotero 插件